Alongside tiny data drop, Caribou plans dose escalation for its first off-the-shelf CAR-T trial

In May, Caribou Biosciences shared impressive early data on its first trial for an off-the-shelf CAR-T therapy, disclosing that four of five patients suffering from B cell non-Hodgkin’s lymphoma had a complete response.

With its EHA presentation coming up Saturday, the Jennifer Doudna-founded biotech has unwrapped more data on its...

Click to view original post